TriSalus Life Sciences, Inc. develops oncology-focused drug-delivery technology and an investigational immunotherapy program for solid tumors. Its Pressure-Enabled Drug Delivery, or PEDD, platform is used through the TriNav Infusion System in interventional radiology procedures, including TARE and TACE, for primary liver cancer and liver metastases.
Company news centers on TriNav commercial performance, clinical and preclinical data for PEDD, studies in liver tumors, research involving nelitolimod, and presentations to interventional radiology audiences. Updates also include quarterly financial results, revenue guidance, capital actions, shareholder voting matters and governance changes tied to the company’s oncology technology strategy.
TriSalus Life Sciences (Nasdaq: TLSI) reported preliminary unaudited results for Q4 and full-year 2025. Q4 2025 revenue was approximately $13.2 million (≈60% YoY) and full-year 2025 revenue was approximately $45.2 million (≈53% YoY), exceeding 2025 guidance. Year-end cash and cash equivalents were approximately $20.4 million, down $2.3 million from the start of Q4. The company set initial 2026 revenue guidance of approximately $60–$62 million. Results are preliminary, unaudited and subject to change pending year-end close and audit.
TriSalus Life Sciences (Nasdaq: TLSI) will host a virtual key opinion leader event on December 15, 2025 at 2:00 PM ET to discuss the TriNav Infusion System and the company's Pressure-Enabled Delivery for Thyroid Artery Embolization (PED-TAE) approach.
Juan C. Camacho, MD, will join company management to review the unmet need and current treatment landscape for symptomatic thyroid disease, explain how PED-TAE targets inferior thyroid arteries to reduce gland size and relieve symptoms for patients ineligible for surgery or conventional therapies, and answer questions from attendees.
Waystar (Nasdaq: WAY) announced it will join the S&P SmallCap 600, effective before market open on September 22, 2025. The company highlighted recent operating strength including double-digit revenue growth over the past 15 months, $1.8 trillion in gross claims processed annually, 115% net revenue retention, and scaled clients up to 15% year-over-year.
Waystar cited product innovation such as AltitudeAI, which the company says accelerates denial appeals 3x faster and boosts overturn rates by 40%+. Membership in the index is expected to broaden the shareholder base, increase institutional visibility, and enhance trading liquidity.
TriSalus Life Sciences (NASDAQ: TLSI) reported $11.6 million revenue for Q3 2025, up 57% YoY and +3% sequentially, driven by TriNav sales in liver-directed applications. Gross margin was 84% versus 86% a year earlier. The company reduced quarterly cash burn by ~50% QoQ and held $22.7 million in cash and equivalents as of September 30, 2025, with reported adjusted EBITDA losses of $5.4 million (improved from $7.2M). Net loss attributable to common stockholders was $41.3 million, largely reflecting preferred-to-common conversion effects. TriSalus reaffirmed 2025 revenue guidance of at least 50% growth and highlighted clinical and investigator-published data for new embolization uses.
TriSalus Life Sciences (Nasdaq: TLSI) said CEO Mary Szela and CFO David Patience will attend investor conferences in November and December 2025. Management will hold one-on-one meetings and deliver corporate overviews at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on Nov 20, 2025 at 2:30 PM ET, and at the 37th Annual Piper Healthcare Conference on Dec 2, 2025 at 3:10 PM ET. Live webcasts will be available, and a webcast replay will be posted for 90 days in the Events section of the TriSalus investor website at www.investors.trisaluslifesci.com.
TriSalus Life Sciences (Nasdaq: TLSI) will host a virtual key opinion leader event on November 12, 2025 at 10:00 AM ET to discuss uterine fibroids and the TriNav Infusion System.
Speakers Nicole Lamparello, MD and Francis Kang, MD will join company management to review the unmet need, current treatment landscape, the Uterine Artery Embolization (UAE) market opportunity, and an overview of the TriNav system with its Pressure-Enabled Drug Delivery™ (PEDD™) approach. A live Q&A will follow the presentations.
TriSalus Life Sciences (NASDAQ: TLSI) will host a third quarter 2025 financial results conference call and webcast on Thursday, November 13, 2025 at 4:30 PM Eastern. A press release with results will be issued prior to the call. Participants must register online to receive dial-in details and a personal PIN by email. The event will be webcast live on the company’s investor relations website and a replay will be available after the event.
Registration is required for phone participation; the webcast link and replay will be accessible via the TriSalus investor relations page.
TriSalus Life Sciences (Nasdaq: TLSI), an oncology company focused on integrating novel delivery technology with standard therapies for solid tumors, announced its participation in two upcoming investor conferences in September 2025.
CEO Mary Szela and CFO David Patience will attend the Cantor Global Healthcare Conference on September 5, featuring a fireside chat at 9:35 a.m. ET, and the Lake Street Capital Markets Best Ideas Growth Conference on September 11. Both events will take place in New York, NY. A webcast replay will be available for 90 days on the company's investor website.
TriSalus Life Sciences (Nasdaq: TLSI) reported strong Q2 2025 financial results, with revenue reaching $11.2 million, representing a 52% year-over-year and 22% quarter-over-quarter growth. The company successfully launched TriNav FLX, expanding its PEDD portfolio with enhanced vessel navigation capabilities.
Key financial metrics include 84% gross margins, operating losses of $7.3 million (improved from $8.2M in 2024), and cash position of $26.5 million. The company reiterated its full-year revenue growth guidance of at least 50% and expects to reach positive adjusted EBITDA in H1 2026.
TriSalus Life Sciences (Nasdaq: TLSI) has published clinical data evaluating its proprietary Pressure-Enabled Drug Delivery (PEDD) technology for thyroid parenchymal embolization using the TriNav® Infusion System. The retrospective single-center study demonstrated promising results in treating symptomatic thyroid disease.
The study of 22 patients showed significant outcomes, including 100% technical and clinical success, 71% of hyperthyroid patients achieving normal thyroid function, and a 73% mean reduction in thyroid gland volume at 6 months. No major complications were reported, with only mild post-procedure symptoms resolving within two weeks.
A multi-institutional registry study (PROTECT, NCT06868459) has been initiated to further validate these findings in a broader setting.